# AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies

> **NCT00135317** · PHASE3 · COMPLETED · sponsor: **Amgen**

## Conditions studied

- Cancer

## Interventions

- **DRUG:** darbepoetin alfa

## Key facts

- **NCT ID:** NCT00135317
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2013-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00135317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00135317, "AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00135317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*